[Corrigendum] Inhibition of Rac1 reverses enzalutamide resistance in castration-resistant prostate cancer
Xiaoliang Chen, Lili Yin, Gan Qiao, Yanhua Li, Baoyuan Li, Yunfeng Bai, Feng Feng
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsTGF-β signaling in diseases · Prostate Cancer Treatment and Research · Cell death mechanisms and regulation
Oncol Lett 20: 2997–3005, 2020; DOI: 10.3892/ol.2020.11823
Following the publication of the above article, an interested reader drew to the authors' attention that, for the Transwell migration assay experiments shown in Fig. 3A on p. 3001, the sh-Ctl/DMSO and sh-Ct/Enza data panels appeared to contain an overlapping section of data, such that these data panels were apparently derived from the same original source where the results of different experiments were intended to have been portrayed.
The authors were able to consult their original data, and realized that this figure had inadvertently been assembled incorrectly. The revised version of Fig. 3, now showing the correct data for the sh-Ct/Enza panel, is shown on the next page. The authors regret that this error occurred in the original published version of this figure, although this did not grossly affect the results or the conclusions reported in this article. All the authors agree with the publication of this Corrigendum, and thank the Editor of Oncology Letters for allowing them the opportunity to publish this; furthermore, they apologize to the readership for any inconvenience caused.